Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies

BACKGROUND: Wilms’ tumor gene 1 (WT1) peptide vaccine and anti-programmed cell death-1 (anti-PD-1) antibody are expected as immunotherapies to improve the clinical outcome of glioblastoma. The aims of this study were to clarify how each immunotherapy affects tumor-infiltrating immune cells (TIIs) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Chisato, Nakata, Jun, Takano, Koji, Nakajima, Hiroko, Hayashibara, Hiromu, Minagawa, Hikaru, Chiba, Yasuyoshi, Hirayama, Ryuichi, Kijima, Noriyuki, Kinoshita, Manabu, Hashii, Yoshiko, Tsuboi, Akihiro, Oka, Yoshihiro, Oji, Yusuke, Kumanogoh, Atsushi, Sugiyama, Haruo, Kagawa, Naoki, Kishima, Haruhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331049/
https://www.ncbi.nlm.nih.gov/pubmed/34355173
http://dx.doi.org/10.1093/noajnl/vdab091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8331049/
https://www.ncbi.nlm.nih.gov/pubmed/34355173
http://dx.doi.org/10.1093/noajnl/vdab091

Ejemplares similares